Neuraxpharm and Dizlin Pharmaceuticals Sign Global Agreement to Co-Develop Wearable Therapy for Advanced Parkinson’s Disease
Wednesday, July 09, 2025
Neuraxpharm Group, a European pharmaceutical company focused on central nervous system (CNS) disorders, has entered into a global co-development agreement with Sweden-based Dizlin Pharmaceuticals. The partnership aims to advance Infudopa SubC®, a wearable drug-device treatment designed for individuals with advanced Parkinson’s disease.
This collaboration marks Neuraxpharm’s first step into the drug-device sector. The company sees this as a major development in its efforts to offer new solutions in neurological care, particularly where existing treatment options are limited.
Infudopa SubC® is a levodopa-carbidopa solution that is delivered through a subcutaneous infusion belt pump. It is intended for patients whose motor symptoms are no longer effectively managed with oral medication. The wearable pump offers a steady and accurate delivery of the medication, providing an alternative to more invasive device-based therapies.
Parkinson’s disease is currently the fastest-growing neurological disorder globally, affecting more than 10 million people. This number is expected to double by 2050. As the condition progresses, many patients find that oral treatments become less effective, and their symptoms worsen. Device-aided therapies like Infudopa SubC® can offer improved symptom control and greater independence.
Through this agreement, Neuraxpharm will take part in the development of Infudopa SubC® and will hold exclusive rights to market the product across Europe, in countries where it operates directly, and through selected partners in other regions such as the United States and Japan.
The deal strengthens Neuraxpharm’s growing strategy of combining pharmaceutical innovation with med-tech solutions. It follows the company’s earlier move into digital health with the commercial launch of a wearable device for epilepsy prediction, developed in partnership with mjn-neuro in 2022.
By combining efforts with Dizlin, Neuraxpharm aims to bring a practical and effective new treatment option to people with advanced Parkinson’s disease, helping them manage their condition more confidently and improve their quality of life.
Source: prnewswire.com
